A Multicentre, Double-blind, Randomised Parallel Group, Placebo- controlled Study of the Effect of long-term treatment with Sativex on Cognitive Function and Mood of Patients with Spasticity due to Multiple Sclerosis

Trial Profile

A Multicentre, Double-blind, Randomised Parallel Group, Placebo- controlled Study of the Effect of long-term treatment with Sativex on Cognitive Function and Mood of Patients with Spasticity due to Multiple Sclerosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Jun 2014

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Multiple sclerosis; Muscle spasticity
  • Focus Pharmacodynamics
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 23 Oct 2013 New source identified and integrated: ClinicalTrials.gov record.
    • 02 Oct 2013 Results have been presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) according to a GW Pharmaceuticals media release.
    • 05 Aug 2013 Top-line results were reported in a GW Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top